SSG 2025: Asa Waldstein on FDA, FTC and NAD enforcement trends

Cassandra Stern

Interview

Apex Compliance’s Asa Waldstein shares valuable insights for those seeking to avoid an FDA warning letter, a competitor case with the NAD or a referral to the FTC due to ad claims non-compliance.

Regulatory scrutiny from the Federal Trade Commission (FTC), National Advertising Division (NAD) and the Food and Drug Administration (FDA) has gained momentum in 2025 across CPG categories, including dietary and nutritional supplements.

At SupplySide Global in October, Asa Waldstein, principal at Apex Compliance and chair of the Supplement Advisory Group, discussed recent cases and shared insights on the latest trends shaping FDA warning letters, FTC oversight and NAD actions.